$3.20 0.16 (+5.26%)
11/6/2009 4:00 PM

Synta Pharmaceuticals Corp. (SNTA)

CAPS Rating: 3 out of 5

A biopharmaceutical company focused on discovering, developing and commercializing small molecule drugs that address severe medical conditions with potential markets, including cancer and chronic inflammatory diseases.

Current Price $3.20 Mkt Cap $108.65M
Open $3.04 P/E Ratio 1.72
Prev. Close $3.04 Div. (Yield) N/A (N/A)
Daily Range $3.04 - $3.34 Volume 117,767
52-Wk Range $1.20 - $9.55 Avg. Daily Vol. 47,000

SNTA News and Commentary

Related News and Articles

Caps

How do you think SNTA will perform vs the S&P 500?

Add Stock to Watchlist

All Members

96 Outperform
7 Underperform
 

All-Star Members

32 Outperform
2 Underperform
 

Wall Street

3 Outperform
1 Underperform
 

Top SNTA Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

FunesDMemorious (98.29)
Submitted August 26, 2008

I believe elesclomal's trial results have been very encouraging, especially in light of its mechanism of action. There is much recent evidence for the critical importance of mitochondria in the cancer problem. Elesclomal is thought to work in part by… More

0 Comments | Reply | Report this Post

zzlangerhans (99.36)
Submitted May 01, 2009

A benevolent deity has given me Synta back to red thumb again. I really thought I had lost this company forever although I did have the consolation of score leadership. Could this be a trick to take away all I have accomplished? Even so, I can't take… More

1 Comment | Reply | Report this Post
SNTA VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from members about SNTA.

Recs

0
Member Avatar zzlangerhans (99.36) Submitted: 11/7/2009 9:19:42 PM : Underperform Start Price: $3.15 SNTA Score: -1.69

Synta crawls back over 100M yet again despite their inability to come to terms with the failure of elesclomol. HSP-90 and preclinical programs do not justify 50M above shareholder equity.

Report this Post 0 Comments | Reply | Permalink

Recs

0
Member Avatar TSIF (98.51) Submitted: 11/5/2009 1:28:21 PM : Underperform Start Price: $2.98 SNTA Score: -6.56

Bios have bitten me lately, both my up and down calls, but I guess there is no cure for my playing them. I've played Synta before and I see little change in the fundamentals. Synta posted a profit today...great for a baby pharm!!! But where did it come from when it has $4 Million per quarter of revenue and $10-22 Million quarterly of R&D and other expenses and no drug on FDA approval list? An accelerated payment from a partnership with GlaxoSmithKline that was cancelled after halting drug testing of it's metastatic melanoma drug, elesclomos, in late stage testing last February. Drug is cancelled, subtract out the payment and we have the same quarterly loss as always. The only good news is more cash in the coffers to continue development of other drugs, but half of their R&D team was cut after the failure of elesclomos to treat metastatic melanoma. Other drugs are still in pre-clinical, two years plus or more away (with the huge assumption that it's approvable, effective, safe, etc), and no signed partners. Deals limit cash exposure. Cash is good until about 2012, but there is no catalyst on the horizon to warrant the boost in Synta's share price after receiving an advance of their milestone payments from GSK on a failed product.

Report this Post 0 Comments | Reply | Permalink

Recs

0
Member Avatar ssbb123 (78.24) Submitted: 9/24/2009 10:29:35 AM : Underperform Start Price: $2.96 SNTA Score: -5.93

From the Annual 10Q filed on 8/4/09
"We have devoted substantially all of our capital resources to the research and development of our drug candidates. Since our inception, we
have had no revenues from product sales. We have never been profitable and, as of June 30, 2009, we had an accumulated deficit of
$424.7 million. We expect to incur significant operating losses for the foreseeable future as we advance our drug candidates from discovery
through preclinical development and clinical trials, and seek regulatory approval and eventual commercialization. We will need to generate
significant revenues to achieve profitability and may never do so."

Founded in 2000, never been profitable, may never be, That's enough for me, red thumb

Report this Post 0 Comments | Reply | Permalink
View All 17 Pitches »

Leaderboard

Find the members with the highest scoring picks in SNTA.

Score Leader

zzlangerhans

zzlangerhans (99.36) Score: +162.01

I stone cold called this shizzle, Synta is my bee-otch

Top
Pick 		Member Name Member
Rating 		Start
Date 		Call Time
Frame 		Start
Price 		Stock
Gain 		S&P
Gain 		Score Commentary
latracia 58.44 2/8/2007 Underperform 1Y $9.67 -66.91% -21.46% +45.45
biomaniac 20.61 8/9/2007 Underperform NS $7.25 -55.86% -23.51% +32.35
BetterMoney77 < 20 12/12/2007 Underperform NS $7.00 -54.29% -25.70% +28.59
joesteinhardt 94.47 10/9/2009 Outperform 5Y $2.98 +7.38% +0.46% +6.92
beginningfool09 < 20 9/23/2009 Outperform 5Y $3.01 +6.31% -0.18% +6.49
expatriot08 84.42 9/23/2009 Outperform 5Y $3.01 +6.31% -0.18% +6.49
burnsme 98.67 9/28/2009 Outperform NS $2.98 +7.38% +1.10% +6.28
greenshooter 86.10 10/19/2009 Outperform 5Y $3.11 +2.89% -1.78% +4.67
pennycruncher < 20 10/19/2009 Outperform 5Y $3.11 +2.89% -1.78% +4.67
outperformONLY < 20 10/19/2009 Outperform 5Y $3.11 +2.89% -1.78% +4.67
View Complete Scorecard »

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Member Name Member
Rating		 Start
Date		 Call Time
Frame		 Start
Price		 Stock
Gain		 S&P
Gain		 Score End Date Commentary
TrackRothCapital 75.81 11/5/2009 Outperform NS $2.80 +14.29% +1.39% +12.89
TrackWachovia 35.10 2/27/2009 Underperform NS $1.51 +111.92% +47.30% -64.62
TrackSusquehanna 74.76 6/2/2008 Outperform NS $7.20 -55.56% -20.55% -35.01
TrackRothCapital 75.81 4/9/2008 Outperform NS $7.88 -80.84% -44.72% -36.11 2/27/2009 @ $1.51
TrackFBRCapitalM 75.98 3/12/2008 Outperform NS $7.00 -12.86% -3.79% -9.07 6/30/2008 @ $6.10
TrackRBCCapMkts 81.74 1/31/2008 Outperform NS $7.23 -79.11% -44.45% -34.66 2/27/2009 @ $1.51
TrackRodmanRen < 20 10/2/2007 Outperform NS $8.06 -81.27% -50.65% -30.61 2/27/2009 @ $1.51
TrackLazardCapit < 20 3/19/2007 Outperform NS $9.50 -84.11% -44.81% -39.30 2/27/2009 @ $1.51
TrackBearStearns 86.38 3/19/2007 Outperform NS $9.85 -67.51% -18.67% -48.84

Featured Broker Partners